Claus currently serves as the Chief Medical Officer at Swissmedic, previously as their head of “Marketing Authorisation” and deputy Chief Executive. Claus joined Swissmedic 2012 to initially lead their Clinical Assessment division.
Prior to that Claus had roles of increasing responsibilities with research-based international pharmaceutical, biotech and medical device organisations (UK, USA, CH). Claus trained as a General Surgeon and had clinical and academic appointments in Trauma, Transplant and Oncologic Surgery.
The Swiss authority is responsible for the authorisation and supervision of therapeutic products across all therapeutic areas in a buzzing life-sciences research and manufacturing hub. Swissmedic is a member of the Access consortium – together with Australia's TGA, Health Canada (HC), Singapore's HSA, and the UK’s MHRA . As a Project Orbis partner Swissmedic also participates in the concurrent review of oncology products coordinated by the US FDA.